Side-by-side comparison of AI visibility scores, market position, and capabilities
E-prescribing, medication history, and patient safety platform processing hundreds of millions of Rx transactions annually. Rockville MD; founded 2000; embedded in hundreds of EHR and clinical workflow platforms; EPCS compliance and medication history retrieval improve prescribing safety for 500K+ providers.
DrFirst is a health IT company that has been at the forefront of e-prescribing and medication management since its founding in 2000. Headquartered in Rockville, Maryland, DrFirst provides e-prescribing for controlled substances (EPCS), medication history retrieval, clinical decision support, and patient medication adherence tools to hospitals, physician practices, long-term care facilities, and health IT vendors. The company processes hundreds of millions of prescription transactions annually and is embedded in a wide range of EHR and clinical workflow platforms through its APIs and SDK integrations.\n\nDrFirst's flagship EPCS solution was among the earliest to achieve DEA compliance for electronic prescribing of controlled substances, a capability that has become essential as regulatory requirements and clinical adoption have expanded across all states. The company's medication history service aggregates pharmacy and payer claims data to give providers a more complete view of a patient's actual medication use, supporting medication reconciliation at transitions of care and reducing adverse drug events. DrFirst also offers Backline, a secure clinical communication platform for care team messaging.\n\nDrFirst occupies a specialized but critical position in the health IT ecosystem, providing medication-related infrastructure that EHR vendors embed in their platforms rather than build independently. This embedded model gives DrFirst broad distribution across the provider market and creates sticky, long-term customer relationships. The company has invested in expanding its clinical intelligence capabilities, including AI-driven prior authorization for specialty medications and smart alerts that surface relevant clinical guidance at the point of prescribing.
Dominant browser-based collaborative UI design platform at ~$600M ARR and $12.5B valuation; Adobe's $20B acquisition blocked by regulators in 2023, Figma remains independent competing with Sketch and Adobe.
Figma is a San Francisco-based collaborative web-based product design platform that has become the dominant tool for UI/UX designers and product teams — enabling real-time multi-user collaboration on interface design, prototyping, and design system management directly in the browser without installing desktop software. Founded in 2012 by Dylan Field and Evan Wallace and backed by Sequoia, Greylock, and Andreessen Horowitz with over $330 million raised, Figma generated approximately $600 million in ARR in 2023, serving 4 million+ designers and product teams at companies including Microsoft, Airbnb, Twitter, and Uber. Adobe announced a $20 billion acquisition offer in 2022, which was blocked by regulators in 2023 — Figma remains independent.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.